New Market Study Published: China Pharmaceuticals & Healthcare Report Q2 2011

New Healthcare market report from Business Monitor International: "China Pharmaceuticals & Healthcare Report Q2 2011"
 
April 20, 2011 - PRLog -- BMI View: China has the world's most attractive emerging pharmaceutical market. Driven by a booming economy and underpinned by political stability, demand for medicines, both generic and patented, will continue to increase. Indicating a long-term commitment to the Asian country, pharmaceutical companies are increasingly investing in research facilities and, to a lesser extent, manufacturing plants. The key downside risk is further pricing pressures, which could intensify in the event of an economic slowdown.

Headline Expenditure Projections

* Pharmaceuticals: CNY385bn (US$56.7bn) in 2010 to CNY452bn (US$69.0bn) in 2011; +17.6% in local currency terms and +21.9% in US dollar terms. Our forecast has been revised up moderately from Q111 due to macroeconomic factors.
 * Healthcare: CNY1,688bn (US$249bn) in 2010 to CNY1,883bn (US$287bn) in 2011; +11.5% in local currency terms and +15.6% in US dollar terms. Our forecast has been revised up moderately from Q111 due to macroeconomic factors.
 * Medical devices: CNY107bn (US$15.8bn) in 2010 to CNY120bn (US$18.3bn) in 2011; +12.3% in local currency terms and +16.3% in US dollar terms. Our forecast has been revised up moderately from Q111 due to macroeconomic factors.


Business Environment Rating: China's score increased from 60.9 out of 100 in Q111 to 62.5 in Q211. The cause was a November 2010 upgrade to the country's pharmaceutical market forecast, resulting in its Industry Rewards score rising from 63 to 67. However, it still remains in fourth position, behind Australia. Within five years, we project that China will become the most attractive pharmaceutical market in Asia Pacific.

Key Trends & Developments

* In December 2010, China's National Development and Reform Commission (NDRC) announced the introduction of price cuts on more than 174 drugs categorised in 17 groups, slashing prices by an average of 19%. This is another example of pricing pressures in emerging pharmaceutical markets.
 * In line with the trend for consolidation among local drugmakers, Sinopharm acquired a 60% stake in Hebei province-based Shijiazhuang Le Ren Tang Pharmaceutical Chain from Le Ren Tang Pharmaceutical Group for CNY1.3bn (US$197.5mn) in January 2011.


BMI Economic View: China's real GDP will expand by 8.3% in 2011. Although BMI's projection is below consensus, this rate of economic expansion will support the country's public and private pharmaceutical markets in the short term. It will also allow investment in medical infrastructure such as hospitals, clinics and pharmacies, especially in the central provinces. As with other industrial sectors, inflation will be a significant concern during 2011.

BMI Political View: China's government is committed to expanding access to medical services in general and pharmaceuticals in particular. The ambitious CNY850bn (US$124.5bn) healthcare reform programme announced in April 2009 will primarily benefit the vast rural population, but also those on low incomes in urban areas. Access to medicine also improved following the August 2009 revision to the National Essential Drugs List (NEDL). A downside risk to our outlook is authorities tightening regulation of over-prescribing, particularly in state hospitals.

For more information or to purchase this report, go to:
-  http://www.fastmr.com/prod/149607_china_pharmaceuticals_h...


Partial Table of Contents:

SWOT Analysis
- China Pharmaceuticals And Healthcare Industry SWOT
- China Political SWOT
- China Economic SWOT
- China Business Environment SWOT
Pharmaceutical Business Environment Ratings
- Table: Asia Pacific Pharmaceutical Business Environment Ratings For Q211
- Rewards
- Risks
China - Market Summary
Regulatory Regime
- Intellectual Property Issues
- Counterfeit Medicines
- Pricing Regime
- Price Cuts
- Reimbursement Regime
Industry Trends and Developments
- Epidemiology
- Communicable Diseases
- Non-Communicable Diseases
- Healthcare Sector
- Hospital Sector
R&D    Activity
- Clinical Trials Activity
- Biotechnology Sector
- Active Pharmaceutical Ingredients (APIs)
- Vaccine Sector
- Overall Market Forecast
- Table: Pharmaceutical Sales Indicators 2007-2015
- Key Growth Factors - Industry
- Table: Healthcare Expenditure Indicators 2007-2015
- Table: Government Healthcare Expenditure Indicators 2007-2015
- Table: Private Healthcare Expenditure Indicators 2007-2015
- Key Growth Factors - Macroeconomic Forecast
- Table: China - Economic Activity
- Prescription Drug Market Forecast
- Table: Prescription Drug Sales Indicators 2007-2015
- Top 10 Therapeutic Classes In China According To Hospital Drug Purchases In Q110
- Patented Drug Market Forecast
- Table: Patented Drug Market Indicators 2007-2015
- Generic Drug Market Forecast
- Table: Generic Drug Sales Indicators 2007-2015
- OTC Medicine Market Forecast
- Table: OTC Medicine Sales Indicators 2007-2015
- Table: Leading OTC Medicine Manufacturers In China According To 2009 Sales
- Medical Device Market Forecast
- Table: Medical Devices Sales Indicators 2007-2015
- Pharmaceutical Trade Forecast
- Table: Exports and Imports Indicators 2007-2015
- Other Healthcare Data Forecasts
- Key Risks to BMI's Forecast Scenario
Competitive Landscape
- Pharmaceutical Industry
- Table: Top 10 Multinationals In China According To Hospital Drug Sales In Q110 (MAT)
- Table: Top 10 Drug Brands In China According To Hospital Purchase Value In Q110 (MAT)
- Table: Top 20 China Or Hong Kong-Based Pharmaceutical Companies According To Market Capitalisation
-

Full Table of Contents is available at:
-- http://www.fastmr.com/catalog/product.aspx?productid=1496...

About Business Monitor International

Business Monitor International (BMI) offers a comprehensive range of products and services designed to help senior executives, analysts and researchers assess and better manage operating risks, and exploit business opportunities, across 175 markets.  BMI offers three main areas of expertise: Country Risk BMI's country risk and macroeconomic forecast portfolio includes weekly financial market reports, monthly regional Monitors, and in-depth quarterly Business Forecast Reports.  Industry Analysis BMI covers a total of 17 industry verticals through a portfolio of services, including in-depth quarterly Country Forecast Reports.  View more research from Business Monitor International at http://www.fastmr.com/catalog/publishers.aspx?pubid=1010

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

# # #

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.
End
Source: » Follow
Email:***@fastmr.com Email Verified
Zip:01267
Tags:Pharmaceutical, Q111, Moderately, Dollar, Currency, Healthcare, Medical, Revised, le, Reform
Industry:Health, Medical, Research
Location:Massachusetts - United States
Account Email Address Verified     Account Phone Number Verified     Disclaimer     Report Abuse
Fast Market Research News
Trending
Most Viewed
Daily News



Like PRLog?
9K2K1K
Click to Share